Literature DB >> 27052802

Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs.

R F Boyd1, S L Boye2, T J Conlon3, K E Erger3, D G Sledge4, I M Langohr4, W W Hauswirth2, A M Komáromy1, S E Boye2, S M Petersen-Jones1, J T Bartoe1.   

Abstract

Adeno-associated virus (AAV) vector-based gene therapy is a promising treatment strategy for delivery of neurotrophic transgenes to retinal ganglion cells (RGCs) in glaucoma patients. Retinal distribution of transgene expression following intravitreal injection (IVT) of AAV is variable in animal models and the vitreous humor may represent a barrier to initial vector penetration. The primary goal of our study was to investigate the effect of prior core vitrectomy with posterior hyaloid membrane peeling on pattern and efficiency of transduction of a capsid amino acid substituted AAV2 vector, carrying the green fluorescent protein (GFP) reporter transgene following IVT in dogs. When progressive intraocular inflammation developed starting 4 weeks post IVT, the study plan was modified to allow detailed characterization of the etiology as a secondary goal. Unexpectedly, surgical vitrectomy was found to significantly limit transduction, whereas in non-vitrectomized eyes transduction efficiency reached upwards to 37.3% of RGC layer cells. The developing retinitis was characterized by mononuclear cell infiltrates resulting from a delayed-type hypersensitivity reaction, which we suspect was directed at the GFP transgene. Our results, in a canine large animal model, support caution when considering surgical vitrectomy before IVT for retinal gene therapy in patients, as prior vitrectomy appears to significantly reduce transduction efficiency and may predispose the patient to development of vector-induced immune reactions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27052802      PMCID: PMC4891289          DOI: 10.1038/gt.2016.31

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  42 in total

1.  Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging.

Authors:  Hyuncheol Kim; Martin J Lizak; Ginger Tansey; Karl G Csaky; Michael R Robinson; Peng Yuan; Nam Sun Wang; Robert J Lutz
Journal:  Ann Biomed Eng       Date:  2005-02       Impact factor: 3.934

2.  Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.

Authors:  Nishanth Gabriel; Sangeetha Hareendran; Dwaipayan Sen; Rupali A Gadkari; Govindarajan Sudha; Ruchita Selot; Mansoor Hussain; Ramya Dhaksnamoorthy; Rekha Samuel; Narayanaswamy Srinivasan; Alok Srivastava; Giridhara R Jayandharan
Journal:  Hum Gene Ther Methods       Date:  2013-03-15       Impact factor: 2.396

3.  Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs.

Authors:  Peter Bell; Guangping Gao; Mark E Haskins; Lili Wang; Meg Sleeper; Huan Wang; Roberto Calcedo; Luk H Vandenberghe; Shu-Jen Chen; Chick Weisse; Elanor Withnall; James M Wilson
Journal:  Hum Gene Ther       Date:  2011-04-11       Impact factor: 5.695

Review 4.  Gene therapy for retinal ganglion cell neuroprotection in glaucoma.

Authors:  A M Wilson; A Di Polo
Journal:  Gene Ther       Date:  2011-10-06       Impact factor: 5.250

Review 5.  Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation.

Authors:  J Wayne Streilein
Journal:  J Leukoc Biol       Date:  2003-08       Impact factor: 4.962

6.  In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous.

Authors:  Deniz Dalkara; Leah C Byrne; Ryan R Klimczak; Meike Visel; Lu Yin; William H Merigan; John G Flannery; David V Schaffer
Journal:  Sci Transl Med       Date:  2013-06-12       Impact factor: 17.956

Review 7.  Immunology of AAV-Mediated Gene Transfer in the Eye.

Authors:  Keirnan Willett; Jean Bennett
Journal:  Front Immunol       Date:  2013-08-30       Impact factor: 7.561

8.  AAV-mediated and pharmacological induction of Hsp70 expression stimulates survival of retinal ganglion cells following axonal injury.

Authors:  J M K Kwong; L Gu; N Nassiri; V Bekerman; R Kumar-Singh; K D Rhee; X-J Yang; W W Hauswirth; J Caprioli; N Piri
Journal:  Gene Ther       Date:  2014-11-27       Impact factor: 5.250

9.  Characterization of intraocular immunopathology following intracameral inoculation with alloantigen.

Authors:  Daniel R Saban; Ian A Elder; Cuong Q Nguyen; W Clay Smith; Adrian M Timmers; Maria B Grant; Ammon B Peck
Journal:  Mol Vis       Date:  2008-03-26       Impact factor: 2.367

10.  Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach.

Authors:  F M Mowat; K R Gornik; A Dinculescu; S L Boye; W W Hauswirth; S M Petersen-Jones; J T Bartoe
Journal:  Gene Ther       Date:  2013-11-14       Impact factor: 5.250

View more
  8 in total

1.  A 2020 vision of ocular gene therapy.

Authors:  Robert E MacLaren
Journal:  Gene Ther       Date:  2020-06-29       Impact factor: 5.250

Review 2.  Assessing retinal ganglion cell damage.

Authors:  C A Smith; J R Vianna; B C Chauhan
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

3.  Retina transduction by rAAV2 after intravitreal injection: comparison between mouse and rat.

Authors:  Mariana S Dias; Victor G Araujo; Taliane Vasconcelos; Qiuhong Li; William W Hauswirth; Rafael Linden; Hilda Petrs-Silva
Journal:  Gene Ther       Date:  2019-09-27       Impact factor: 5.250

Review 4.  From Bench to Bed: The Current Genome Editing Therapies for Glaucoma.

Authors:  Meihui He; Rong Rong; Dan Ji; Xiaobo Xia
Journal:  Front Cell Dev Biol       Date:  2022-05-16

Review 5.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

Review 6.  The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery.

Authors:  Maya Ross; Ron Ofri
Journal:  Neural Regen Res       Date:  2021-09       Impact factor: 5.135

7.  Systemic and local immune responses to intraocular AAV vector administration in non-human primates.

Authors:  Divya Ail; Duohao Ren; Elena Brazhnikova; Céline Nouvel-Jaillard; Stephane Bertin; Seyed Bagher Mirashrafi; Sylvain Fisson; Deniz Dalkara
Journal:  Mol Ther Methods Clin Dev       Date:  2022-01-22       Impact factor: 6.698

8.  Longitudinal Evaluation of Hyper-Reflective Foci in the Retina Following Subretinal Delivery of Adeno-Associated Virus in Non-Human Primates.

Authors:  Eduardo Rodríguez-Bocanegra; Fabian Wozar; Immanuel P Seitz; Felix F L Reichel; Alex Ochakovski; Kirsten Bucher; Barbara Wilhelm; K Ulrich Bartz-Schmidt; Tobias Peters; M Dominik Fischer
Journal:  Transl Vis Sci Technol       Date:  2021-05-03       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.